ODOMZO Drug Patent Profile
✉ Email this page to a colleague
When do Odomzo patents expire, and when can generic versions of Odomzo launch?
Odomzo is a drug marketed by Sun Pharm and is included in one NDA. There are three patents protecting this drug.
This drug has one hundred and eighteen patent family members in forty-nine countries.
The generic ingredient in ODOMZO is sonidegib phosphate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the sonidegib phosphate profile page.
DrugPatentWatch® Generic Entry Outlook for Odomzo
Odomzo was eligible for patent challenges on July 24, 2019.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be March 30, 2036. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ODOMZO?
- What are the global sales for ODOMZO?
- What is Average Wholesale Price for ODOMZO?
Summary for ODOMZO
| International Patents: | 118 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 80 |
| Clinical Trials: | 6 |
| Patent Applications: | 583 |
| Drug Prices: | Drug price information for ODOMZO |
| What excipients (inactive ingredients) are in ODOMZO? | ODOMZO excipients list |
| DailyMed Link: | ODOMZO at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ODOMZO
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for ODOMZO
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Gruppo Oncologico del Nord-Ovest | Phase 2 |
| Melanoma Institute Australia | Phase 2 |
| Anne Chang | Phase 2 |
Pharmacology for ODOMZO
| Drug Class | Hedgehog Pathway Inhibitor |
| Mechanism of Action | Smoothened Receptor Antagonists |
US Patents and Regulatory Information for ODOMZO
ODOMZO is protected by three US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of ODOMZO is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting ODOMZO
Crystaline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-Methyl-4'-(trifluo- romethoxy) [1,1'-biphenyl]-3-Methanamide monophosphate, and process of preparation thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Salts of N-[6-cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(t- rifluoromethoxy)[1,1'-biphenyl]-3-carboxamide
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Compounds and compositions as hedgehog pathway modulators
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF BASAL CELL CARCINOMA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharm | ODOMZO | sonidegib phosphate | CAPSULE;ORAL | 205266-001 | Jul 24, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Sun Pharm | ODOMZO | sonidegib phosphate | CAPSULE;ORAL | 205266-001 | Jul 24, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Sun Pharm | ODOMZO | sonidegib phosphate | CAPSULE;ORAL | 205266-001 | Jul 24, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ODOMZO
When does loss-of-exclusivity occur for ODOMZO?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
China
Patent: 5906616
Patent: LDE225单磷酸盐的晶型及其制备方法 (Crystal form of LED 225 monophosphate and preparation method thereof)
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 79198
Patent: FORME CRISTALLINE DU MONOPHOSPHATE DE N-[6-(FORME CIS-2,6-DIMÉTHYLMORPHOLINE-GROUPE-4)PYRIDINE-GROUPE-3]-2-MÉTHYL-4'-(TRIFLUOROMÉTHOXY)[1,1'-BIPHÉNYL]-3-FORMAMIDE ET SON PROCÉDÉ DE PRÉPARATION (CRYSTAL FORM OF N-[6-(CIS FORM-2,6-DIMETHYLMORPHOLINE-4-GROUP)PYRIDINE-3- GROUP]-2-METHYL-4'-(TRIFLUOROMETHOXY)[1,1'-BIPHENYL]-3- FORMAMIDE MONOPHOSPHATE, AND PREPARATION METHOD THEREFOR)
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering ODOMZO around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Mexico | 2008014190 | COMPUESTOS Y COMPOSICIONES COMO MODULADORES DE LA SENDA DE HEDGEHOG. (COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS.) | ⤷ Sign Up |
| Croatia | P20130597 | ⤷ Sign Up | |
| Taiwan | 201016686 | Salts of N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ODOMZO
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2021328 | C02021328/01 | Switzerland | ⤷ Sign Up | VERTRETERLOESCHUNG |
| 2021328 | 64/2015 | Austria | ⤷ Sign Up | PRODUCT NAME: SONIDEGIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ, HYDRAT ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/15/1030 (MITTEILUNG) 20150818 |
| 2021328 | CR 2015 00057 | Denmark | ⤷ Sign Up | PRODUCT NAME: SONIDEGIB ELLER ET FARMACEUTISK ACCEPTABELT SALT, HYDRAT ELLER SOLVAT DERAF, HERUNDER SONIDEGIBFOSFAT; REG. NO/DATE: EU/1/15/1030 20150818 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
